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Stalking influenza by vaccination 
with pre-fusion headless HA mini-
stem
Sophie A. Valkenburg1,2, V. Vamsee Aditya Mallajosyula3, Olive T. W. Li2, Alex W. H. Chin2, 
George Carnell4, Nigel Temperton4, Raghavan Varadarajan3 & Leo L. M. Poon2
Inaccuracies in prediction of circulating viral strain genotypes and the possibility of novel reassortants 
causing a pandemic outbreak necessitate the development of an anti-influenza vaccine with increased 
breadth of protection and potential for rapid production and deployment. The hemagglutinin (HA) stem 
is a promising target for universal influenza vaccine as stem-specific antibodies have the potential to 
be broadly cross-reactive towards different HA subtypes. Here, we report the design of a bacterially 
expressed polypeptide that mimics a H5 HA stem by protein minimization to focus the antibody 
response towards the HA stem. The HA mini-stem folds as a trimer mimicking the HA prefusion 
conformation. It is resistant to thermal/chemical stress, and it binds to conformation-specific, HA stem-
directed broadly neutralizing antibodies with high affinity. Mice vaccinated with the group 1 HA mini-
stems are protected from morbidity and mortality against lethal challenge by both group 1 (H5 and H1) 
and group 2 (H3) influenza viruses, the first report of cross-group protection. Passive transfer of immune 
serum demonstrates the protection is mediated by stem-specific antibodies. Furthermore, antibodies 
indudced by these HA stems have broad HA reactivity, yet they do not have antibody-dependent 
enhancement activity.
Vaccination is one the most effective means for public health control of infectious diseases. A vaccine against 
influenza virus has been available for over 70 years, yet influenza still causes epidemics or pandemic with substan-
tial morbidity and mortality. The protective responses induced by current human influenza vaccines still primar-
ily depend on vaccine-induced neutralizing antibodies (nAbs) against the HA head1. However, the continually 
evolving influenza virus evades herd immunity induced through natural infection and vaccination by means of 
antigenic drift and shift. These antigenic drift and shift events render vaccine stockpiling unviable in case of an 
outbreak or pandemic. In addition, a major shortcoming of current influenza vaccines is its long production time 
because of existing egg-based or cell-based vaccine manufactory pipelines. Thus, there is a need for novel influ-
enza vaccines with increased breadth of protection and potential for rapid production and deployment.
The HA of influenza viruses, except those recently detected from bats, can be classified into 2 phylogenetic 
groups based on sequence conservation, group 1 (H1, H2, H5, H6, H8, H9, H11, H12, H13 and H16) and group 2 
(H3, H4, H7, H10, H14 and H15)2. The HA protein on the virion surface is a trimer, in a pre-fusion state as HA0, 
and is then cleaved by cellular proteases to HA1 and HA23. The majority of the HA1 chain forms the globular 
head, which contains the receptor-binding site (RBS). The accumulation of amino acid changes and glycosylation 
sites in the globular head domain might render pre-existing antibody responses obsolete. By contrast, the HA 
stem, predominantly comprised of the HA2 domain, is structurally conserved across HA subtypes4,5. The con-
served stem domain contains a greater proportion of vulnerable sites targeted by broadly neutralizing antibodies 
(bnAbs) than the variable head domain6. Importantly, anti-stem broadly neutralizing antibodies (bnAbs) are 
detectable in some individuals at a low level, suggesting they can be induced naturally by infection and optimized 
by vaccination. Thus, structure-guided immunogen design targeting conserved, vulnerable sites in the stem of 
influenza HA might be a promising approach to ‘universal’ influenza vaccine development.
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Humoral responses against the stem domain post infection or vaccination are weak relative to those against 
the head domain. Thus, eliciting cross-protective, stem-directed bnAbs remains challenging7. Different strate-
gies, such as headless HA virus8, prime-boost with a chimeric HA protein9,10, sequential infection with different 
influenza subtypes11, or polypeptide mimics to the HA stem12–16, have been employed to elicit bnAbs antibodies 
towards this domain. Animals immuninized by these new strategies are shown to be protected from challenges 
with viruses that are of the same HA subtype and/or group (e.g. H1 against H5). However, in vivo data showing 
protections of a group 1 HA stem vaccine against a lethal challenge of a group 2 HA virus or vice versa, have not 
been demonstrated or were unsuccessful. In this study, using our newly developed H5-mini stem polypeptide 
and our previously reported H1-mini stem as immunogens12, we describe the use of a group 1 HA mini-stem to 
induce protection against both group 1 and group 2 viruses.
Results and Discussion
Highly pathogenic H5N1 virus is endemic in some countries. We therefore developed and tested the pro-
tective efficacy of a novel H5-based HA stem immunogen designed from influenza A H5N1 (VN/04: A/Viet 
Nam/1203/04) (GenBank Accession: AAW80717.1) virus. We also characterized our previously designed H1 
mini-stem (PR/34: A/PR/8/34)12 in a mouse model against heterologous influenza virus challenge, and evaluated 
the vaccine mediated antibody responses. The recombinant protein vaccine was administered in combination 
with AddaVax, a squalene-based oil-in-water nanoemulsion similar to MF59 and AS03 adjuvants, which are 
licensed for human use in Europe for influenza vaccines17.
Conserved residue patches in the HA stem comprising the ‘antigenic signatures’ of bnAbs were identified 
by a comprehensive H5 HA sequence (n = 2642) conservation analysis (Fig. 1A,B). An epitope focused stem 
immunogen, H5HA10-Foldon (hereafter referred to as H5F), was designed by analyzing the interaction network 
within H5 HA (VN/04)18 and mapped by generating an all-atom residue contact matrix using the in-house soft-
ware PREDBURASA19. H5F consists of three stem derived fragments; HA1: 14–37, 286–319 and HA2: 41–113 
(Fig. 1D,E). These fragments collectively comprise a significant fraction of the antibody (Ab) footprint of the 
bnAb CR6261, and minimally perturbed the pre-fusion HA stem interactions (Fig. 1C). However, protein min-
imization exposes a previously buried hydrophobic patch within the full-length HA, that can potentially lead to 
aggregation. Therefore, we re-surfaced this HA1 region with polar amino acid substitutions: I297T, I300T, and 
I302N. Also, the surface exposed, single cysteine residue (HA1 C305) in the HA mini-stem that can potentially 
form a non-native, inter-molecular disulfide bond was mutated to serine. We introduced aspartate mutations 
(HA2 V66D and L73D) in the HA mini-stem to destabilize the low-pH conformation of HA (Fig. 1E) as described 
previously20. The individual stem fragment termini were connected using soluble, flexible GSA linkers (Fig. 1E). 
A synthetic, trimerization motif “Foldon”21 was fused at the C-terminus of the HA mini-stem to promote oli-
gomerization (Fig. 1D,E). Analysis of the sequence conservation and structural homology of the designed HA 
mini-stems with the stem domain of viruses used for challenge in this study (H5N1: A/Indo/05 (Indo/05), pdm 
H1N1/2009: A/California/04/09 (Ca/09) and mouse adapted H3N2: A/HK/68 (HK/68)), showed that mimick-
ing the pre-fusion HA stem interactions to present a ‘functional’ binding surface is an essential pre-requisite 
to elicit broadly, cross-protective immune response(s), highlighting the need to present ‘conformational’ 
rather than ‘sequential’ epitopes to the immune system (Fig. 1F). The designed HA mini-stem was expressed in 
E. coli and recovered by a single, affinity-purification step. Biophysical characterization of H5F indicated a stable, 
well-folded, α -helical protein (Figure S1A–C), which formed a homogenous trimer in solution (Figure S1D). 
Proteins expressed in a prokaryotic system lack post-translational modifications (PTMs), therefore our E. coli 
expressed HA mini-stem lacks glycosylation and may have enhanced accessibility of conserved stem epitopes 
resulting in increased cross-reactive Ab responses relative to native protein immunization22.
Stem-directed bnAbs are robust probes for evaluating HA conformation23–25, since their epitopes are disrupted 
in the extended, low-pH conformation of HA. H5F bound the stem-directed, conformation selective bnAbs 
with high affinity (11.6 ± 1.4 to 43.5 ± 10.7 nM) (Table S1, Figure S2). The antigen-antibody complex of H5F 
with CR6261-IgG was specifically pulled down with Protein G beads (Figure S3). These results indicate that HA 
mini-stem closely mimics the native, pre-fusion conformation of HA. Additionally, the HA mini-stem was resistant 
to diverse, pharmaceutically relevant stress conditions and retained binding to CR6261-IgG (Table S2, Figure S1E). 
The physical and chemical stability of HA mini-stem suggests it can be transported and stored without requiring 
a cold-chain, facilitating stockpiling as well as deployment during an outbreak in low-resource settings.
The immunogenicity of adjuvantated HA mini-stem designed from HPAI H5N1 (VN/04) was assessed 
by extensive characterization of the sera from vaccinated mice. We also probed the Ab response elicited by 
H1HA10-Foldon (referred to as H1F), a previously characterized “headless” HA stem-fragment immuno-
gen designed from influenza A H1N1 (PR/34) virus12. The breadth of Ab response elicited by HA mini-stem 
vaccination was probed by enzyme-linked immunosorbent assay (ELISA) and biolayer interferometry (BLI) 
(Fig. 2 and Fig. S4, Table S3) against an extensive panel of recombinant HA proteins. Two-dose vaccination 
with HA mini-stem significantly enhanced the magnitude of cross-reactive Ab responses relative to a single-dose 
(Fig. 2A,B). Furthermore, lower off-rates (koff) of secondary sera versus primary sera binding to HA indicates 
affinity maturation (Tables S4 and S5). Positive control sera from recovered mice with H5N2 (A/Eurasian Wigeon/
MP4610/2007) or H1N1 (pdm Ca/09) virus challenge showed weak HA-stem binding and significantly lower HA 
cross-reactivity, which is consistent with the immunodominance of the hypervariable HA1 head domain during 
natural infection (Fig. 2A,B). The Abs elicited by the HA mini-stem after two immunizations showed broad HA 
cross-reactivity and bound group 1 HAs (H1/H5/H2) with high affinity (Fig. 2C,D).
The binding of HA mini-stem to the pan-influenza bnAb, FI6v3 (Table S1, Figure S2), and the potential for 
developing a broadly reactive antibody response by our vaccine motivated us to test the sera against influenza 
A group 2 HAs (H3/H7). Encouragingly, the Abs elicited by the designed immunogens also bound H3 and H7 
HAs with modest affinity, and low-level binding to influenza B HA (Fig. 2C-E). Antibodies elicited by the HA 
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Figure 1. Design of HA mini-stem from HPAI H5N1 A/Viet Nam/1203/2004 HA. (A) All full-length H5N1 
HA sequences isolated from human hosts (n = 215) were analyzed and the conservation score (Q-score) obtained 
from a multiple sequence alignment was mapped onto a monomer of the surface representation of the H5 HA 
A/Viet Nam/1203/2004 trimer (PDB ID: 2FK0), and the remaining HA in light gray. (B) Conservation analysis 
was extended to include all avian influenza H5 HA sequences (n = 2427) (C) The conserved HA stem fragments 
included in H5F (cartoon representation). One monomer was colored based on the Q-score. The second 
monomer was colored as described in (E), whilst the third monomer is shown in light gray. Dashed lines represent 
connecting linkers. Schematic of (D) full-length H5 HA and ‘headless’ HA stem-fragment, H5F. Intra-subunit 
(solid lines, black) and inter-subunit (solid line, blue) disulfide bonds are shown. The polybasic cleavage site 
(blue), fusion peptide (tan), trans-membrane domain (dark green) and the cytoplasmic tail (orange) are indicated. 
Red brackets (< /> ) are the start/stop sites of each subunit in the crystal structure (PDB ID: 2FK0). The crystal 
structure numbering was followed here. Dashed lines indicate linkers. A synthetic trimerization motif, foldon 
(light green), was appended at the C-terminus of the disulfide-free HA mini-stem to promote oligomerization. 
The expression vector derived N-terminal His-tag (dark blue) that facilitates a facile, one-step Ni-NTA affinity 
purification is also indicated. (E) Sequence of H5F colored according to the schematic in panel (D). Site-specific 
mutations (bold and underlined) were introduced to prevent protein aggregation. Aspartate (D) mutations 
(bold, italics and underlined) were introduced to destabilize the low-pH conformation of HA. (F) The sequence 
conservation in the HA stem fragments between the vaccine candidates and influenza virus challenge strains was 
determined by pairwise sequence alignment (http://www.ebi.ac.uk/Tools/psa/emboss_stretcher/). The structural 
similarity (main chain) between HA stem fragments across different influenza virus strains was calculated by a 
topology independent comparison of modeled structures using the CLICK server (http://mspc.bii.a-star.edu.sg/
minhn/output/143882270252.html). (A–C) were rendered using PyMOL.
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Figure 2. The HA mini-stem vaccines elicit broad, cross-reactive neutralizing Abs in mice. The binding 
of sera (total IgG) to HA proteins was probed by ELISA/BLI, from day 21 post primary (pooled n = 8) or 
secondary vaccine dose (pooled n = 20). (A–C) The sera Abs (total IgG) were captured using Protein G (ProG) 
biosensors and the kinetics of binding to HA proteins was determined using an Octet RED96 instrument. 
Lower equilibrium dissociation constant (KD) indicates higher affinity. Convalescent sera from mice that 
recovered from a sub-lethal H5N2 (Wigeon/07) or H1N1 (pdm Ca/09) virus challenge was used as positive 
controls. The BLI determined sera reactivity profile of primary and secondary (A) H5F and (B) H1F immune 
sera (n.b. indicates no detectable binding). (C) The BLI determined sera reactivity profile of secondary immune 
sera against a panel of HAs from influenza A groups 1 and 2, and influenza B using BLI. (D) Immune sera 
competition with the bnAb CR6261 for binding to H1 HA (pdm Ca/09). CR6261 was captured on amine 
reactive biosensors and the interaction with full-length H1 HA (pdm Ca/09) was monitored by BLI using 
the Octet RED96 instrument. The binding of H1-HA (pdm Ca/09) protein to CR6261 was also probed after 
incubation (30 mins) of the protein with different sera dilutions (as indicated). The decreased binding of H1 HA 
(pdm Ca/09) to the immobilized CR6261 in the presence of vaccine sera indicated the existence of competing 
antibodies. Pooled serum (n = 5–20 mice) was used, experiments were repeated two to three times and 
performed in duplicate. (E) Vaccine sera tested in direct ELISA specific for different recombinant HA proteins.
www.nature.com/scientificreports/
5Scientific RepoRts | 6:22666 | DOI: 10.1038/srep22666
mini-stem compete with the bnAb CR6261 for binding to H1N1 (pdm Ca/09) HA (Fig. 2D), therefore they may 
also inhibit virus replication by targeting the stem region.
A yeast surface display (YSD) library expressing HA fragments of heterologous influenza A H1 HA (pdm 
Ca/09) and H3 HA (HK/68) were used to determine whether these mini-stem can induce antibodies that are spe-
cific to the HA2 stem region (Figure S5). The HA mini-stem vaccine serum showed higher-level H1-YSD library 
binding than H1N1 (pdm Ca/09) convalescent sera (Figure S5A). The binding of HA mini-stem vaccine serum 
for the H3-YSD library was also higher than H1N1 (pdm Ca/09) convalescent sera, which had no detectable bind-
ing (Figure S5D). Sequencing of HA-YSD clones bound by H1F and H5F serum indicated an immunodominant 
antibody response towards the HA stem (Figure S5H), therefore our vaccine successfully stimulates stem-specific 
antibodies.
The HA mini-stem immunized mice were challenged with heterologous influenza viruses: HPAI H5N1 
(Indo/05), pandemic H1N1 (pdm Ca/09) and H3N2 (HK/68) to determine the in vivo protective efficacy of 
stem-specific antibodies. H5F (VN/04, clade 1) conferred robust protection against an unmatched, heterologous 
HPAI H5N1 (Indo/05, clade 2.1) virus challenge with minimal weight loss (< 5%) and no signs of clinical mor-
bidity (especially no neurological symptoms) (Fig. 3A), whilst H1F vaccine (PR/34) conferred partial heterosub-
typic protection against HPAI H5N1 (Indo/05) virus challenge. Further, the mice immunized with H1F and H5F 
survived the lethal pandemic H1N1 (pdm Ca/09) virus challenge with reduced symptoms and reduced symptom 
severity (Fig. 3B).
Previous attempts to elicit cross-group protection via HA stem-focused immune response have had limited 
success with even modest challenge doses, such as the H5-chimeric HA vaccine model for H3N2 challenge10. 
Encouragingly, immunization with our H1F and H5F HA mini-stem, designed from group 1 influenza A viruses, 
conferred significant protection against a lethal influenza A group 2 H3N2 (HK/68) virus challenge (Fig. 3C), 
with 80% survival of H1F vaccinated mice. Whilst protection was clearly evident from our vaccine by increased 
survival and reduced symptom severity from each challenge experiment, vaccination did not significantly alter 
viral loads at day 3 post-infection. Encouragingly, at day 7 post-infection, lower viral loads or complete clearance 
was observed in few of the vaccinated mice (not statistically significant). However, the lung inflammation profile 
was not significantly different in vaccinated mice as compared to the naive group (Figure S6), in terms of neu-
trophil and macrophage influx (Figure S6A,B), alternative activated macrophages (Figure S6C), protein leakage 
within the lung (Figure S6D) or overall histology by H&E staining (Figure S6E). Therefore, whilst our vaccine 
is clearly protective, the mode of protection from our mini-stem vaccine is not directly related to limiting virus 
replication or inflammation in the lung. This is consistent with recent studies wherein stem-directed Abs although 
protective from mortality, failed to prevent infection16 or reduce lung viral loads15.
Vaccine protection is antibody mediated, as passive transfer of vaccine serum prior to lethal HPAI H5N1 
(Indo/05) virus challenge increased survival (for homologous H5F vaccination), and reduced symptom severity 
(Fig. 3D). The lung viral loads were reduced by 8-fold for H1F sera and 3-fold for H5F sera, with viral clearance in 
1 out of 3 mice for both the H1F and H5F groups. This increased protective effect on viral loads in passive transfer 
relative to active vaccination, may be due to the volume of sera used for transfer (500 μl) or possible interference 
from other vaccine specific immune responses during vaccination itself.
We next examined the neutralizing activity of HA mini-stem induced antibodies against a panel of viral 
subtypes to probe the mechanism of vaccine protection. In contrast to earlier studies10,16,26,27, neutralization of 
unmatched viral subtypes was observed in a stringent microneutralization (MN) assay (Fig. 4A), such as against 
H1N1 virus for heterologous H5F serum (1:640) and unmatched H1F serum (> 1:1,280). The HA mini-stem 
antisera also showed neutralization activity (1:80–1:160) against influenza A group 2 (H3N2/H7N7) viruses from 
both H1F and H5F vaccine groups. The heterologous reactivity of the serum is consistent with a level of heterosub-
typic protection offered by the vaccine. However, neutralization of influenza H5 viruses (group 1) from multiple 
clades could not be detected in the MN assay, including convalescent H5N2 (A/Eurasian Wigeon/MP4610/2007) 
serum for the homologous H5N2 virus. Other studies have also had difficulty in detecting H5-specific neutralisa-
tion16,28,29. In the more sensitive pseudotype based microneutralization assay (pMN), the HA mini-stem vaccine 
sera showed detectable activity against unmatched H5 viral strains, Indo/05 (clade 2.1) and QH/1A (clade 2.2) 
(Fig. 4B), whilst there was no activity for the vaccine homologous strain VN/1203 (clade 1).
The levels of neutralization observed in the MN and pMN assay agree with our in vivo mouse data that HA 
mini-stem immunized sera may not control initial virus replication, as high viral loads are reached at day 3 
post infection (Fig. 3A–C). It is possible that a significant fraction of HA mini-stem induced antibodies are 
non-neutralizing. Interestingly, the lack of correlation between neutralizing antibody titer and protection was also 
recently observed in animals immunized by HA-stem nanoparticles16. The findings from this previous study and 
those from us suggest that HA-stem specific, non-neutralizing antibodies may also play a role in heterosubtypic 
protection to influenza virus. Non-neutralizing antibodies may be protective by recruiting other immune factors 
or cells for ADCC and complement15,30,31, altering virus fusion32, assembly or interfering with the virus life cycle33.
We also hypothesize that subtle differences between the neutralization epitopes of the HA stem among differ-
ent viral subtypes may explain the disparate neutralization efficacy of the HA mini-stem polyclonal sera against 
the tested viruses. H5F and H1F vaccination induced a polyclonal Ab response which bind multiple epitopes 
within the HA-stem, resulting in H1N1, H3N2 and H7N7 virus neutralization, whilst these same epitopes may 
not be present in H5 viruses. Thus, protection from HPAI H5N1 infection by vaccine serum (Fig. 3D), may use an 
alternate immune mechanism which is yet to be determined. Further study on the modes of protection of these 
stem-specific antibodies will be needed.
The HA mini-stem elicits high affinity, stem-specific antibodies with protective potential. Further immune sera 
characterization revealed that vaccination with Addavax does not skew the balance of the natural Ab response, 
as the IgG1/IgG2a ratio (which reflects the Th1/Th2 balance) is similar to convalescent H3N2 (HK/68) sera 
(Figure S7A). The IgA and IgM levels in the sera are comparable to those in unvaccinated mice (Figure S7B,C). 
www.nature.com/scientificreports/
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Vaccination also results in a broadly binding early antibody response from day 7 after H3N2 infection, which is 
otherwise undetectable in unvaccinated mice (Figure S7D), and the response is maintained to at least day 28-post 
challenge (Figure S7E). Furthermore, the magnitude and avidity of vaccine (H5F and H5) and cross-reactive (H3) 
Ab response remained relatively unchanged over time (Figure S7F,H) up to 120 days post vaccination.
Figure 3. HA mini-stem immunization provides robust protection against lethal heterologous virus 
challenge in mice. Female BALB/c mice were vaccinated twice at 3 weeks interval by the intramuscular (i.m.) 
route with 20 μg of HA mini-stem adjuvanted with Addavax. PBS with Addavax (PBS + A) vaccinated mice 
were used as a negative control. Vaccinated mice were challenged 21 days after the secondary immunization 
with (A) HPAI H5N1 (Indo/05, 30TCID50), (B) H1N1 (pdm Ca/09, 1.36 × 106 TCID50) or (C) H3N2 (HK/68, 
2.5 × 106 TCID50) virus. Survival and symptom severity were monitored for 14 days post virus challenge (n = 5). 
Lung viral loads at day 3 and day 7 were determined by standard TCID50 on MDCK cells (n = 3–6). (D) Passive 
transfer of immune sera (day 21 after the secondary immunization, heat inactivated, pooled n = 20 mice). 
500 μl of serum was given intraperitoneally (i.p.) prior to HPAI H5N1 (Indo/05, 30TCID50) virus challenge of 
naïve BALB/c mice (n = 8). Survival, symptom severity (n = 5), and day 7 viral loads (n = 3) were determined. 
Statistics for survival was determined by a log-rank test. Statistics for symptom severity and lung viral loads 
versus PBS + A controls were determined Student’s t-test. (P-values: #< 0.05, *< 0.01, **< 0.001).
www.nature.com/scientificreports/
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There have been some concerns over antibody dependent enhancement (ADE) for stem-specific antibodies, 
resulting in increased influenza infection of vaccinated animals32. Whilst no increase in lung viral loads was 
observed in vaccinated mice (Fig. 3), to ensure our vaccine did not increase influenza virus entry, an in vitro 
infection in the presence of immune sera was performed (Fig. 4C). Raji cell infection rate in the presence of naïve 
mouse sera was 20%, whilst H1N1 convalescent sera had a 1.5% infection rate, an impressive 13-fold reduc-
tion. Whilst H1FS had a modest 15.4% H1N1 infection rate (1.3-fold reduction). H5FS had relatively compa-
rable infection rate as naïve mouse serum, and therefore did not inhibit heterologous H1N1/H3N2 virus entry. 
Furthermore, H1N1-convalescent sera potentially increased H3N2 infection rate by 1.5-fold, which was not 
observed for our vaccine sera.
Our experiments showed that HA mini-stem vaccination generated high-titer, protective Ab responses. 
Further investigations are required to determine in more detail the protective mechanisms of HA stem-specific 
antibodies, which may act by alternate mechanisms such as interruption of virus life-cycle during entry, fusion, 
replication or by recruiting host immunity via antibody-dependent cellular cytotoxicity (ADCC) or complement 
activation.
We successfully engineered a H5-based HA mini-stem, using only a quarter of the full length HA, therefore 
focusing the immune response to the conserved epitope of known bnAbs in the stem domain of HA. The H5 HA 
mini-stem protein folds as a trimer, in a pre-fusion conformation of the HA stem. The physico-chemically toler-
ant HA mini-stem immunogens are resistant to thermal denaturation and pH-dependent conformational switch-
ing, thus no cold chain is required for the vaccination schedule. The recombinant protein vaccine is purified from 
E. coli, and can therefore be readily mass produced. These are essential properties for the vaccine production pipe-
line, pre-pandemic stockpiling and large scale production. FluBlok, a recombinant trivalent-HA protein influenza 
vaccine expressed in baculovirus is already licenced by the FDA for human use (http://www.fda.gov/NewsEvents/
Newsroom/PressAnnouncements/ucm335891.htm). This sets a precendent for the use of recombinant protein 
based anti-influenza vaccines in humans.
The HA mini-stem vaccination elicited broad, cross-reactive, neutralizing Ab responses that breached the 
HA group-specific barrier and conferred robust protection against lethal heterologous influenza A virus chal-
lenge from both group 1 and 2 lineages. Recently there have been other studies targeting the conserved HAstem 
using chimeric HA10, mini-HA stem15 or multivalent display on nanoparticles16. However, ours is the first study 
Figure 4. HA-stem specific neutralizing antibodies are CD4 dependent and do not augment viral entry. 
(A) The virus neutralization potency of ‘headless’ HA stem immunized mice sera was tested in a standard 
microneutralization assay against a panel of influenza viruses, and the lowest sera dilution able to neutralize 
100TCID50 of a given virus is reported. Naïve mouse sera was used as a negative control, and convalescent 
sera from H1N1 (pdm Ca/09) or H5N2 (LPAI, Wigeon/07) virus challenge were used as positive controls. 
Experiments were performed at least 3 times. (B) In vitro neutralization activity of HA mini-stem vaccine serum 
against a panel of H5 pseduotyped virus particles. IC50 titer is the reciprocal of sera dilution at which half-
maximal neutralization was observed. IC50 titer of zero indicates no detectable neutralization. (C) Antibody 
dependent enhancement was assessed by H1N1 (pdm Ca/09) or H3N2 (HK/68) infection of Raji cells in the 
presence of vaccine sera, convalescent sera or naïve mouse sera for 6 hours. Influenza NP expression of Raji cells 
was assessed by flow cytometry. % NP expression is shown, experiment was perfomred twice, in triplicate.
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to demonstrate the in vivo protective efficacy of a group 1 vaccine, against both group 1 (H5N1 and H1N1) and 
group 2 (H3N2) viruses with impressive survival rates. Our study provides a promising strategy for developing a 
HA stem-based ‘universal’ influenza vaccine.
Materials and Methods
Sequence conservation analysis. All non-identical, full-length influenza H5 HA sequences isolated 
from human (n = 215) and avian (n = 2427) hosts deposited in a public database (http://www.ncbi.nlm.nih.
gov/genomes/FLU/FLU.html) were analyzed. The sequences were clustered at 99% homology to avoid over-rep-
resentation using CD-HIT (Cluster Database at High Identity with Tolerance)34 to filter-out a total of 867 
(n = 60/807 from human/avian hosts) unique, representative H5 HA sequences. Subsequently, these sequences 
were multiply aligned using CLUSTAL35. The measure of residue conservation at every position in the sequence is 
given by the quality score (Q-score) in the alignment file. These scores were binned and mapped onto the crystal 
structure of H5 HA A/Viet Nam/1203/2004 [Protein Data Bank (PDB) ID: 2FK0]18.
Gene synthesis and protein purification. The E. coli codon-optimized gene sequence of H5F was syn-
thesized (GenScript, USA) with a stop codon at the 3′ end. Subsequently, the gene was cloned in-frame with the 
vector (pET-28a (+ ) (Novagen)) derived N-terminal His-tag between the NdeI (5′ end) and HindIII (3′ end) 
restriction sites. The HA mini-stem proteins used in this study were purified using a similar protocol as described 
previously12. The purified protein was dialysed (against PBS containing 1 mM EDTA (pH 7.4)) and concentrated 
to ~5 mg/ml. The protein identity was confirmed by ESI-MS (electrospray ionization-mass spectroscopy).
Viruses and recombinant full-length HA proteins. Viruses and full-length influenza A HAs (Sino 
Biological Inc., Beijing, China) are listed as indicated; H1N1 A/California/04/2009 (pdm Ca/09), H1N1 A/Puerto 
Rico/8/1934 (PR/34), H1N1 A/Brevig Mission/1/1918 (BM/18), H2N2 A/Japan/305/1957 (Ja/57), H5N1 A/Viet 
Nam/1194/2004 (VN/04), H5N1 A/Indonesia/5/2005 (Indo/05), H3N2 A/Hong Kong/1/1968 (HK/68), H3N2 A/
Brisbane/10/2007 (Bris/07), and H7N7 A/Netherlands//219/03 (Ned/03). Influenza B HAs (Sino Biological Inc., 
Beijing, China); B/Brisbane/60/2008 (Bris/08) and B/Florida/4/2008 (Fl/08).
Circular dichroism. A Jasco J-715 C spectropolarimeter flushed with nitrogen gas was used to record circular 
dichroism (CD) spectra for all protein samples. The spectra were acquired at 25 °C at a scan rate of 50 nm/min 
using a 1 mm path-length quartz cuvette. The response time was set to 4 s with a bandwidth of 2 nm. The repre-
sented data was averaged over five consecutive scans and corrected for buffer (PBS, pH 7.4) contributions. Mean 
residue ellipticity (MRE) was calculated as described previously36.
Thermal denaturation of H5F (in PBS, pH 7.4) was followed by monitoring the CD-signal at 208 nm between 
15–90 °C with a 1 °C/min gradient. The reversibility of thermal unfolding was determined by repeating the scan 
after cooling the heated sample.
Fluorescence spectroscopy. A Jasco FP-6300 spectrofluorometer was used to acquire the intrinsic fluo-
rescence measurements for all the protein samples at 25 °C. The samples were excited at a wavelength of 280 nm, 
and fluorescence emission was monitored from 300–400 nm. The excitation and emission slit widths of the spec-
trofluorometer were set at 3 nm and 5 nm, respectively. The represented data was averaged over five consecutive 
scans and corrected for buffer signals. Fluorescence spectra of the native protein were recorded in PBS (pH 7.4). 
The protein was denatured in 7 M guanidine hydrochloride (GdmCl) to record the unfolded state fluorescence.
Size exclusion chromatography – Multi angle light scattering (SEC-MALS). The oligomeric state 
of H5F under native conditions was determined at 25 °C by gel filtration chromatography on a Superdex-200 
analytical gel filtration column (GE HealthCare) equilibrated with PBS (pH 7.4) at a flow rate of 0.5 ml/min. 
The column was calibrated using a broad range of molecular weight markers (GE HealthCare). Alternatively, 
for molecular weight determination, the Superdex-200 analytical gel filtration column (GE HealthCare) was 
connected with in-line UV, refractive index and triple-angle MALS scattering (miniDAWN TREOS, Wyatt 
Technology) detectors. ASTRA software was used for data analysis.
Surface plasmon resonance (SPR). Binding affinity of HA mini-stem (H5F) and full-length H5 HA 
(VN/04) (Sino Biological Inc.) to the stem-directed bnAbs; CR6261-IgG, F10-scFv and FI6v3-scFv was deter-
mined by SPR experiments using a Biacore 3000 optical biosensor (Biacore, Uppsala, Sweden) as described pre-
viously12, except the sensor surface was regenerated with multiple injections of 2 M MgCl2 after every binding 
event. The trimeric concentration of H5F and H5 HA (VN/04) were used to fit the data. The kinetic parameters 
were obtained by globally fitting the data to a 1:1 Langmuir interaction model using BIA EVALUATION software 
(version 3.1).
Biolayer interferometry (BLI). The binding affinity of H5F, after subjecting to diverse, pharmaceutically 
relevant stress condition(s) (as indicated in Table S2), to the conformation-specific bnAb CR6261 was determined 
by BLI using an Octet RED96 instrument (Pall ForteBio, CA, USA). CR6261 in PBST (PBS with 0.05% Tween 20, 
pH 7.4) was captured on amine reactive (AR2G) biosensor tips.
The competition of HA mini-stem immunized mice sera for binding to H1 HA (pdm Ca/09) was also deter-
mined using CR6261 immobilized on AR2G tips. The binding of H1 HA (pdm Ca/09) to CR6261 was probed in 
the absence and presence of different dilutions (as indicated) of HA mini-stem vaccinated mice sera.
The kinetic parameters for the binding of sera to HA proteins was determined by BLI. The total IgG was cap-
tured from the pooled mice sera using Protein G (ProG) biosensor tips. The IgGs from all test sera were captured 
to an equal thickness (~2.0 nm). A concentration series of HA proteins (2.0 μM, 1.0 μM and 0.5 μM) was used to 
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determine the apparent equilibrium dissociation constant (KD). An unliganded sensor (reference sensor) was 
used during every interaction analysis as a control for non-specific analyte binding. The sensor surface(s) were 
regenerated after each binding experiment with 2 M MgCl2. The maximal binding capacity of the ProG tips was 
comparable after every regeneration event as tested by binding of a control sera (convalescent H1N1 (pdm Ca/09) 
sera) with 1.0 μM of H1 HA (pdm Ca/09).
The trimeric concentration of HA proteins were used to fit all the BLI data. All the traces were corrected for 
non-specific signals (if any) and processed using the ForteBio Data Analysis Software (v8.0) and fit globally using 
a simple 1:1 Langmuir interaction model.
Pull-down assay. The specificity of H5F and CR6261 IgG complex was probed by a targeted IgG pull-down 
assay using Protein-G beads (GE HealthCare). H5F was incubated with CR6261 at different molar ratios for 2 h 
at 4 °C adjusted with PBS (pH 7.4) to a final volume of 30 μl. This was followed by the addition of Protein-G beads 
(10 μl) to capture IgG. The tubes were spun down at 3000 × g for 15 mins at 4 °C and the unbound supernatant 
was separated from the beads. After two rounds of washes (with PBS, pH 7.4), the antibody bound to the beads 
was eluted (10 μl of 100 mM Glycine.HCl, pH 3.0) and neutralized (2.5 μl of with 1 M Tris.HCl, pH 9.0). The 
unbound and eluted fractions were analyzed simultaneously by SDS-PAGE and stained with Coomassie.
Mice. Female 6 week-old BALB/c mice were vaccinated twice 21 days apart via the intramuscular route 
with 20 μg of antigen in 100 μl of PBS, with 1:1 Addavax adjuvant (Invivogen), and challenged with influenza 
virus 21 days later. PBS with Addavax (PBS + A) vaccinated mice were used as a negative control. For influ-
enza challenge, anesthetized mice were infected intranasally with 25μl of H3N2 HK/68 (A/HK/1/68-MA20C, 
2.5 × 106 TCID50), pandemic H1N1 Ca/09 (A/California/04/2009, 1.36 × 106 TCID50) or HPAI H5N1 Indo/05 
(A/Indonesia/05/2005, 30TCID50). Serum was collected by cardiac puncture at time-points as indicated. Lungs 
were collected for determining infectious viral lung titre by standard TCID50 assay on MDCK cells, and histology. 
For immune cell profiling, bronchoalveolar lavage (BAL, a washing of the lung) and mediastinal lymph nodes 
(MLN, which drain the lower respiratory tract) were collected at day 3 and day 7. All experiments that involved 
HPAI H5N1 were conducted in BSL3 laboratory. All experimental procedures were conducted in accordance with 
the standards of humane animal care by the criteria outlined in the “Guide for the Care and Use of Laboratory 
Animals” prepared by the National Research Council, USA (2011) and approved by the Committee on the Use of 
Live Animals in Teaching and Research, The University of Hong Kong (http://www.lau.hku.hk/content/ethics/
ethics.htm).
Microneutralization assay (MN). Pooled serum (n = 5 controls, n = 20 vaccine groups) was heat inacti-
vated for 90 mins at 56 oC. Two-fold serial dilutions from 1:5 to 1:3200 of serum were prepared in virus medium 
(MEM, 100 U/ml penicillin and 100 μg/ml streptomycin). An equal volume of 200TCID50/35 μl of influenza 
virus was added to the sample dilutions (final serum dilution 1:10 to 1:1280) and incubated for 2 hours at 37 °C, 
5% CO2. Then 35 μl of antibody/virus was added to MDCK cells and incubated for 72 hours at 37 °C, 5% CO2. 
Standard haemagglutination assay and visualization of cytopathic effect was used to measure virus inhibition.
Pseudotype based microneutralization (pMN) assay. The HA mini-stem vaccine sera were tested in 
a pseudotype virus particle entry inhibition assay as described previously37,38. Serial dilutions of the test sera were 
incubated with 1 × 106 relative luminescence units (RLUs) of pseudotypes/well in 96-well flat-bottomed white 
plates (Nunc) in a final volume of 50 μl at 37 °C for 1 h. After the incubation, 1.5 × 104 HEK293T cells were added 
to each well. The plates were subsequently incubated for another 48 h at 37 °C. The luminescence signals were 
assayed using the Bright-Glo assay system (Promega). The half-maximal inhibitory concentrations (IC50) of entry 
inhibition were determined using SigmaPlot.
Enzyme linked immunosorbent assay (ELISA). Briefly, recombinant HA protein (Sino Biological Inc.) 
and HA-Foldon vaccine (80 ng/ml) were coated on ELISA plates (Nunc-Immuno MaxiSorp, NUNC) overnight. 
Following FBS blocking, and washing, diluted serum samples were bound for 2 hours, washed and detected by 
anti-mouse IgG1-HRP (Invitrogen) as the secondary antibody. TMB/peroxide was used as substrate and the reac-
tion was stopped by addition of sulfuric acid (R&D systems), and absorbance read at 450 nm.
Influenza A Haemagglutinin yeast surface display epitope mapping (HA-YSD). H3 HA-YSD 
and H1 HA-YSD library were constructed as previously described39. Yeast surface expressing peptides were con-
structed from random digestion of the HA fragments derived from the H3N2 (HK/68) HA gene, and H1N1 (pdm 
Ca/09). Thirty individual clones that could reach each pooled sample in each library were randomly selected for 
sequencing study. Sequences were then aligned to the orginal H3 (HK/68) or H1 (pdm Ca/09) HA sequence.
Immune cell profiling. Cells were subject to FcR blocking (anti-CD16/CD32, BD Bioscience), and then 
stained with one of three cocktails containing a panel of monoclonal antibodies for innate and adaptive immune 
cells (all Biolegend unless otherwise indicated), for 30 mins on ice. Cocktail 1: F4/80-PE, I-AE-PerCPCy5.5, 
CD11b-APCy7, Gr1-PECy7, IA8-APC, CD11c-FITC. Cocktail 2: CD3-APC, CD4-APCCy7, CD8-PerCPCy5.5, 
NK1.1/Dx5-FITC, γ δ T-PE and B220-PECy7. Cocktail 3: F4/80-PECy7, CD11b-APCCy7, I-AE-PerCPCy5.5, 
MMR-APC, IL-4 Rα -PE, iNOS-FITC (BD Bioscience).
For intracellular stains, cells were fixed in fixation/permeabilsation buffer (eBioscience) for 30 mins on ice, and 
stained with iNOS-FITC in Perm wash buffer (BD Bioscience). Cells were finally fixed with 100 μl of 4% PFA for 
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20 mins on ice, and then washed and stained with DAPI in PBS for 10 mins on ice. Samples were acquired by flow 
cytometry on a FACS LSR Fortessa and analyzed with FlowJo software.
In vitro antibody dependent enhancement for immune sera. Raji cells (Promega) (1 × 105) were 
incubated with 25 μl of immune H1F or H5F serum (from 21 days post secondary vaccination, heat inactvated, 
pooled n = 5), H1N1 convalescent sera or naïve mouse sera. Cells were infected with an MOI of 4 of H3N2 
(HK68) or H1N1 (pdm Ca/09) virus in the presence of sera for 16 hours in MEM (1%P/S). Cells were then fixed 
(BD cytofix/cytoperm buffer), and stained with NP-FITC (Abcam) in BD permiabilisation buffer for 30 mins on 
ice. Samples were acquired by flow cytometry on a FACS LSR Fortessa and analyzed with FlowJo software.
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